Brexit uncertainty a factor in Shionogi's move from London

12 March 2019
shionogi-big

As lawmakers in the UK Parliament prepare to vote, again, on the Prime Minister’s EU withdrawal deal, the impact of Brexit is already being felt in the pharmaceutical industry.

Just five years after Japanese drugmaker Shionogi (TYO: 4507)  established its European base in London, the firm is jumping ship to the Netherlands, reacting to Brexit-related uncertainty. The choice of destination was no doubt inspired by the relocation of the the European Medicines Agency to Amsterdam.

While the firm has not commented on the reports, the Financial Times says the plan will include Shionogi  “merging its UK-based operation with a Dutch subsidiary.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical